focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Regulatory News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)- Shire plc AMENDMENT

28 Dec 2018 11:13

RNS Number : 7227L
JPMorgan Securities Plc
28 December 2018
 

AMENDMENT

INCREASED EQUITY PURCHASES BY 42,235 TO 10,858,117

DECREASED EQUITY SALES BY 350,000 TO 9,754,154

ADDED EQUITY SWAP PURCHASES OF 302,151

ADDED EQUITY SWAP SALES OF 941,913

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Shire plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Joint Financial Adviser to Takeda Pharmaceutical Company Limited

(d) Date dealing undertaken:

21 December 2018

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes, Takeda Pharmaceutical Company Limited

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

(GBP)

Lowest price per unit paid/received

(GBP)

 

Ordinary Shares

Purchases

 

Sales

10,858,117

 

9,754,154

48.0000

 

46.0000

32.0000

 

42.0000

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

 

Ordinary Shares

Equity Swaps

 

Long

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short

8,861

17,645

8,800

2,255

24,302

112

8,806

10,000

8,760

24,558

8,755

240,000

20,000

15,164

49,551

18,801

14,000

8,758

3,781

2,834

10,000

10,000

100,000

12,751

50,000

3,789

10,131

8,685

748

 

16,287

34,967

445,650

491,889

441,218

50,000

50,000

9,698

59,880

34,277

25,000

1,913

279,188

81,086

83

394

9,418

232

18,000

1,248

25,000

43,732

25,000

25,000

200,000

276,758

44.6522 GBP

44.8121 GBP

44.8801 GBP

44.8921 GBP

44.8937 GBP

44.8950 GBP

44.9103 GBP

45.0715 GBP

45.0722 GBP

45.0827 GBP

45.0868 GBP

45.1040 GBP

45.1108 GBP

45.1224 GBP

45.1278 GBP

45.1389 GBP

45.1624 GBP

45.1649 GBP

45.1773 GBP

45.1856 GBP

45.2193 GBP

45.2221 GBP

45.2312 GBP

45.2378 GBP

45.2500 GBP

45.2550 GBP

45.4384 GBP

45.4421 GBP

45.4562 GBP

 

44.8950 GBP

44.8952 GBP

44.8955 GBP

44.8959 GBP

44.8979 GBP

44.8984 GBP

44.9017 GBP

44.9030 GBP

44.9040 GBP

44.9085 GBP

44.9568 GBP

44.9914 GBP

45.0118 GBP

45.0426 GBP

45.0427 GBP

45.0606 GBP

45.0844 GBP

45.0890 GBP

45.1044 GBP

45.2525 GBP

56.6611 USD

57.0137 USD

57.0188 USD

57.4144 USD

58.2325 USD

58.2387 USD

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

(GBP)

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(GBP)

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(GBP)

Ordinary Shares

Call Option

 

Call Option

 

 

Call Option

 

 

Put Option

 

Put Option

 

Put Option

Exercising

 

Exercised Against

 

Exercised Against

 

Exercising

 

Exercising

 

Exercised Against

12,300

 

45,000

 

 

11,000

 

 

100

 

8,000

 

2,200

32.00

 

42.00

 

 

44.00

 

 

46.00

 

46.00

 

48.00

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable) (GBP)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

28 December 2018

Contact name:

Alwyn Basch

Telephone number:

020 7742 7407

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERLLFLLFFLTFIT
Date   Source Headline
8th Jan 20195:30 pmGNWDirector/PDMR Shareholding
8th Jan 20193:20 pmRNSForm 8.3 - Shire plc
8th Jan 20193:19 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20193:13 pmRNSForm 8.3 - Shire plc
8th Jan 20193:07 pmRNSForm 8.5 (EPT/NON-RI)
8th Jan 20192:28 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20192:23 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20192:21 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20191:57 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20191:27 pmRNSForm 8.3 - Shire plc
8th Jan 201912:31 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 201912:29 pmRNSForm 8.3 - Takeda Pharmaceutical
8th Jan 201912:27 pmRNSForm 8.3 - Shire plc
8th Jan 201911:42 amRNSForm 8.5 (EPT/NON-RI)
8th Jan 201911:33 amRNSForm 8.5 (EPT/NON-RI)- Shire Plc
8th Jan 201910:49 amRNSForm 8.5 (EPT/RI)
8th Jan 201910:41 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 201910:26 amRNSForm 8.5 (EPT/RI)- Shire plc
8th Jan 20199:51 amRNSForm 8.3 - Shire Plc
8th Jan 20198:44 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
8th Jan 20197:00 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20197:00 amGNWScheme becomes effective
7th Jan 20195:00 pmGNWHolding(s) in Company
7th Jan 20193:42 pmRNSForm 8.5 (EPT/RI) - Amendment
7th Jan 20193:20 pmRNSForm 8.3 - Shire plc
7th Jan 20193:02 pmRNSForm 8.3 - Shire plc
7th Jan 20193:00 pmRNSForm 8.5 (EPT/NON-RI)
7th Jan 20193:00 pmRNSForm 8.3 - Shire plc
7th Jan 20192:59 pmRNSForm 8.3 - Takeda Pharmaceutical
7th Jan 20192:50 pmPRNForm 8.3 - Shire Plc
7th Jan 20192:49 pmRNSForm 8.3 - Shire plc
7th Jan 20192:47 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 20192:45 pmBUSForm 8.3 - Shire plc
7th Jan 20191:55 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 20191:54 pmRNSForm 8.3 - Shire plc
7th Jan 20191:39 pmRNSForm 8.3 - [Shire Plc]
7th Jan 20191:32 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
7th Jan 20191:29 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
7th Jan 201912:57 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201912:56 pmRNSForm 8.3 - Shire plc
7th Jan 201912:42 pmRNSForm 8.5 (EPT/NON-RI)
7th Jan 201911:52 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201911:43 amBUSForm 8.3 - SHIRE PLC
7th Jan 201911:30 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201911:27 amRNSForm 8.3 - Shire plc
7th Jan 201911:01 amRNSForm 8.5 (EPT/RI)- Shire plc
7th Jan 201910:59 amRNSForm 8.5 (EPT/NON-RI)- Shire Plc
7th Jan 201910:35 amRNSForm 8.5 - Shire plc
7th Jan 201910:16 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
7th Jan 201910:13 amRNSForm 8.5 (EPT/RI) - Amendment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.